Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma

This is a phase 1 study evaluating the safety and feasibility of laser interstitial thermal therapy (LITT) followed by lomustine (CCNU) for recurrent glioblastoma in adults. The primary aim is to evaluate the safety of the combination of LITT plus lomustine based on the assessment of treatment-related adverse events and the feasibility of completing LITT + lomustine in the proposed timeframe. The secondary aim is to assess overall survival for up to 2 years after the first dose of lomustine.

NCT Number	NCT07145112
Lead Sponsor	University of California, Davis Collaborators: National Cancer Institute (NCI)
Conditions	Glioblastoma
Enrollment	20 participants
Start Date	2025-10-01
Primary Completion	2027-07 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2025-10-09